AU
UK
CA
NZ
IND
US
Shares of Verona Pharma PLC American Depositary Share (NASDAQ: VRNA) continue to trade near record highs, with analysts offering a mixed outlook for the clinical-stage biopharmaceutical firm. HC Wainwright reiterated its “Neutral” rating on Verona in a note issued Monday, raising its price target …
Longevity Health Holdings, Inc. (Nasdaq:XAGE) disclosed on July 14, 2025, that it has entered into a definitive all-stock merger agreement with THPlasma, a company engaged in plasma collection under the True Health Inc. umbrella. The transaction values THPlasma at USD 59 million, with an …
NovoCure Limited (NASDAQ: NVCR) has drawn a varied response from analysts, as its stock continues to trade at a discount compared to its 52-week high. On Tuesday, MarketBeat Ratings reported that LADENBURG THALM/SH SH reiterated a “Buy” rating for the medical equipment company and …
Haleon (LSE/NYSE: HLN) has broken ground on its newGBP130 million Global Oral Health Innovation Centrein Weybridge, Surrey. The project marks a significant step in the company’s expansion of its oral health research and development infrastructure. Once completed, the centre will act as a hub …
Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE) announced the publication of new discoveries featured on the cover ofScience. The article,“Mining the CRBN Target Space Redefines Rules for Molecular Glue-induced Neosubstrate Recognition,”presents how Monte Rosa’s AI and machine learning engine uncovered a broad range of human …
Mesoblast (Nasdaq: MESO; ASX: MSB)announced that it has reached alignment with the U.S. Food and Drug Administration (FDA) on key components required to file a Biologics License Application (BLA) for its cell therapy candidate Revascor® (rexlemestrocel-L) for the treatment of ischemic heart failure with …
BofA Securities issued a notable downgrade forProKidney Corp. (NASDAQ: PROK)on Monday, shifting its rating fromNeutraltoUnderperformand sharply reducing its price target from USD3.00 to USD1.00 per share. The reassessment follows a combination of revised expectations for ProKidney’s lone therapeutic candidate, REACT, and growing caution regarding …
Autolus Therapeutics plc (NASDAQ:AUTL), a clinical-stage biopharmaceutical company focused on programmed T cell therapies, has announced updated results from its ongoing FELIX trial evaluating obe-cel, an autologous CD19 CAR T-cell therapy, in adults with relapsed or refractory (r/r) CD19-positive B-cell acute lymphoblastic leukemia (B-ALL).
PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) announced updates related to its Founded Entity, Vor Bio (Nasdaq: VOR), following two major financial transactions. Vor Bio has entered an exclusive global license agreement with RemeGen Co., Ltd. (HKEX: 9995, SHA: 688331), excluding China, Hong Kong, …
Evotec SE (Frankfurt Stock Exchange: EVT; Nasdaq: EVO) has announced its participation in the NURTuRE-AKI consortium, a longitudinal research initiative focused on acute kidney injury (AKI) and its progression to chronic kidney disease (CKD). The study targets both adult and pediatric cardiac surgery patients …
Please wait processing your request...